Cytomegalovirus Infections Clinical Trial
Official title:
Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection in Allogeneic Hematopoietic Cell Transplant Recipients
To evaluate the safety and efficacy for treatment of persistent CMV infection in hematopoietic cell transplant (HCT) recipients.
HCT recipients who are receiving immunosuppressive agents to control graft versus host
diseases (GVHD) are at high risk for serious CMV infection due to CMV reactivation or
reinfection during their post-transplant period.
Antiviral agents used to treat CMV infection have well-known side effects such as bone marrow
suppression causing cytopenia and renal toxicities. Therefore, patients in a serious
condition would have a higher probability of antiviral treatment-related toxicities and also
increased possibility for prolonged antiviral treatment, thus development of antiviral
resistance and risk of treatment failure.
Allogeneic HCT recipients are typically lack of these CMV-specific T cells during the
post-transplant period and their immune function can be further repressed especially when
they are on additional immunosuppressive agents to prevent GVHD. Therefore, these patients
may benefit from CMV-specific T cell adoptive transfer.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03950414 -
A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients
|
Phase 1 | |
| Recruiting |
NCT04690933 -
AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
|
||
| Withdrawn |
NCT04936971 -
Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
|
Phase 4 | |
| Recruiting |
NCT02671318 -
Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence
|
Phase 4 | |
| Completed |
NCT01325636 -
Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00228202 -
Genotyping of Cytomegalovirus From Patients in Israel
|
N/A | |
| Completed |
NCT00031421 -
Neonatal CMV-Ganciclovir Follow-up Study
|
N/A | |
| Completed |
NCT00005496 -
Inflammation, Infection, and Future Cardiovascular Risk
|
N/A | |
| Terminated |
NCT03262194 -
Relevance of Gastric Aspirate in HCMV Detection
|
||
| Completed |
NCT04478474 -
Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients
|
||
| Recruiting |
NCT05370976 -
Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation.
|
Phase 2 | |
| Active, not recruiting |
NCT02943057 -
Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis
|
Phase 4 | |
| Completed |
NCT02538172 -
Cell-mediated Immunity for Prevention of CMV Disease
|
N/A | |
| Completed |
NCT02642822 -
The Epidemiologic Study of Human Cytomegalovirus（CMV） in Female Students of Xiamen University
|
N/A | |
| Completed |
NCT02134184 -
The Influence of Chronic CMV Infection on Influenza Vaccine Responses
|
Phase 4 | |
| Completed |
NCT00673868 -
Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants
|
Phase 1 | |
| Active, not recruiting |
NCT05089630 -
A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06058858 -
Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
|
||
| Active, not recruiting |
NCT04904614 -
Letermovir Use in Heart Transplant Recipients
|
Phase 4 | |
| Completed |
NCT01986010 -
Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)
|
Phase 1 |